

## **PolyPid to Participate in the Lytham Partners Spring 2025 Investor Conference on May 29, 2025**

PETACH TIKVA, Israel, May 20, 2025 (GLOBE NEWSWIRE) — PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Spring 2025 Investor Conference, taking place virtually on Thursday, May 29, 2025.

### **Company Webcast**

The webcast presentation will take place at 10:15 a.m. ET on Thursday, May 29, 2025. The webcast can be accessed by visiting the conference home page at <https://lythampartners.com/spring2025/> or directly at <https://app.webinar.net/QyL1ZkGZK8z>. The webcast will also be available for replay following the event.

### **1×1 Meetings**

Management will be participating in virtual one-on-one meetings throughout the event. To arrange a meeting with management, please contact Lytham Partners at [1x1@lythampartners.com](mailto:1x1@lythampartners.com) or register for the event at <https://lythampartners.com/spring2025invreg/>.

### **About PolyPid**

PolyPid Ltd. (Nasdaq: PYPD) is a late-stage biopharma company aiming to improve surgical outcomes. Through locally administered, controlled, prolonged-release therapeutics, PolyPid’s proprietary PLEX (Polymer-Lipid Encapsulation matrix) technology pairs with Active Pharmaceutical Ingredients (APIs), enabling precise delivery of drugs at optimal release rates over durations ranging from several days to months. PolyPid’s lead product candidate D- PLEX100 is in Phase 3 clinical trial for the prevention of abdominal colorectal surgical site infections. In addition, the Company is currently in preclinical stages to test the efficacy of OncoPLEX for the treatment of solid tumors, beginning with glioblastoma.

For additional Company information, please visit <http://www.polypid.com> and follow us on Twitter and LinkedIn.

### **Contacts:**

PolyPid Ltd.  
Ori Warshavsky  
COO – US  
908-858-5995

IR@Polypid.com

**Investors:**

Brian Ritchie

LifeSci Advisors

212-915-2578

britchie@lifesciadvisors.com

